BML, Inc. (TYO:4694)

Market Cap	131.94B +14.6%
Revenue (ttm)	150.26B +4.9%
Net Income	7.75B +23.7%
EPS	203.45 +26.7%
Shares Out	37.48M
PE Ratio	17.30
Forward PE	15.83
Dividend	125.00 (3.62%)
Ex-Dividend Date	Mar 30, 2026

Volume	107,800
Open	3,420.00
Previous Close	3,450.00
Day's Range	3,415.00 - 3,525.00
52-Week Range	2,963.00 - 4,385.00
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1955
• Employees: 4,558
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4694

Financial Performance

In fiscal year 2026, BML, Inc.'s revenue was 150.26 billion, an increase of 4.94% compared to the previous year's 143.19 billion. Earnings were 7.75 billion, an increase of 23.71%.